Nifty

:

25285.35

Sensex

:

82500.82

103.55 (0.41%)
328.72 (0.40%)

Login

Nifty
Sensex

:
:

25285.35
82500.82

103.55 (0.41%)
328.72 (0.40%)

Alivus Life Sciences Ltd.

Pharmaceuticals & Drugs

Rating :

57/99

BSE: 543322 | NSE: ALIVUS

Watchlist

NSE BSE

933.80

10-Oct-2025

Open
High
Low
Previous Close

943
949.85
931.25
944.20

Volume
Traded Value (lacs)
52 Week High
52 Week Low

41108
38511815.6
1251
850

Stock Summary

Market Cap(Crs)
Stock P:E
Face Value

11,443.72
23.09
2

Enterprise Value(Crs)
Dividend Yield
Price:Book Value

11,372.48
0.54%
3.91

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

10 Years
5 Years
3 Years

-
4.83
3.37

EBITDA CAGR (%)

10 Years
5 Years
3 Years

-
2.92
1.22

PAT CAGR (%)

10 Years
5 Years
3 Years

-
6.67
1.32

P:E (Median)

8 Years
5 Years
3 Years

-
-
20.68

P:BV (Average)

8 Years
5 Years
3 Years

-
-
3.91

EV:EBITDA (Average)

8 Years
5 Years
3 Years

-
-
13.71

Earnings Forecasts:

(Updated: 04-10-2025)

Description 2024 2025 2026 2027
Adj EPS 39.63 41.46 47.86 55.61
P/E Ratio 23.56 22.52 19.51 16.79
Revenue 2386.88 2600.15 2948.98 3353.35
EBITDA 682.58 748.76 861.48 970.85
Net Income 485.63 530.88 611.63 681.7
ROA 15.51 14.2 14.5
P/B Ratio 4.06 3.53 3.06 2.47
ROE 18.86 16.94 17.13 16.1
FCFF 242.94 144.5 273
FCFF Yield 2.13 1.27 2.4
Net Debt -492.24 -105.75 -152.95 -285.85
BVPS 229.92 264.87 305.1 377.4

Quarterly Results

Standalone Figures in Rs. Crores /

Consolidated

Description Jun 25 Jun 24 Var% Mar 25 Mar 24 Var% Dec 24 Dec 23 Var% Sep 24 Sep 23 Var%
Net Sales 601.85 588.62 2.25% 649.54 536.60 21.05% 641.84 572.80 12.05% 506.88 595.36 -14.86%
Expenses 429.54 429.13 0.10% 451.11 395.15 14.16% 451.54 400.25 12.81% 372.52 428.28 -13.02%
EBITDA 172.31 159.48 8.04% 198.43 141.45 40.28% 190.31 172.56 10.29% 134.36 167.08 -19.58%
EBIDTM 28.63% 27.09% 30.55% 26.36% 29.65% 30.12% 26.51% 28.06%
Other Income 8.98 5.49 63.57% 10.09 3.13 222.36% 10.46 1.69 518.93% 8.53 5.37 58.85%
Interest 1.25 0.35 257.14% 1.26 0.36 250.00% 0.46 0.39 17.95% 0.34 0.40 -15.00%
Depreciation 17.06 14.39 18.55% 15.97 14.53 9.91% 15.16 13.18 15.02% 15.09 13.13 14.93%
PBT 162.98 150.24 8.48% 191.29 129.68 47.51% 185.15 160.68 15.23% 127.46 158.93 -19.80%
Tax 41.45 38.76 6.94% 49.42 31.74 55.70% 48.19 41.92 14.96% 32.14 40.19 -20.03%
PAT 121.53 111.48 9.02% 141.87 97.94 44.85% 136.96 118.77 15.32% 95.32 118.74 -19.72%
PATM 20.19% 18.94% 21.84% 18.25% 21.34% 20.73% 18.80% 19.94%
EPS 9.91 9.09 9.02% 11.56 7.98 44.86% 11.16 9.68 15.29% 7.77 9.68 -19.73%

Description Jun 25 Jun 24 Var% Mar 25 Mar 24 Var% Dec 24 Dec 23 Var% Sep 24 Sep 23 Var%
Net Sales 0.00 0.00 0 0.00 0.00 0 0.00 0.00 0 0.00 0.00 0
Expenses 0.00 0.00 0 0.00 0.00 0 0.00 0.00 0 0.00 0.00 0
EBITDA 0.00 0.00 0 0.00 0.00 0 0.00 0.00 0 0.00 0.00 0
EBIDTM 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Other Income 0.00 0.00 0 0.00 0.00 0 0.00 0.00 0 0.00 0.00 0
Interest 0.00 0.00 0 0.00 0.00 0 0.00 0.00 0 0.00 0.00 0
Depreciation 0.00 0.00 0 0.00 0.00 0 0.00 0.00 0 0.00 0.00 0
PBT 0.00 0.00 0 0.00 0.00 0 0.00 0.00 0 0.00 0.00 0
Tax 0.00 0.00 0 0.00 0.00 0 0.00 0.00 0 0.00 0.00 0
PAT 0.00 0.00 0 0.00 0.00 0 0.00 0.00 0 0.00 0.00 0
PATM 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EPS 0.00 0.00 0 0.00 0.00 0 0.00 0.00 0 0.00 0.00 0

Annual Results

Standalone Figures in Rs. Crores

Right to Left

Description TTM Mar 25 Mar 24 Mar 23 Mar 22 Mar 21 Mar 20 Mar 19 Mar 18
Net Sales 2,400.11 2,386.88 2,283.21 2,161.22 2,123.21 1,885.16 1,537.31 886.42 0.25 Net Sales Growth 4.65% 4.54% 5.64% 1.79% 12.63% 22.63% 73.43% 354468.00% Cost Of Goods Sold 1,063.44 1,037.44 968.64 984.12 1,019.28 877.46 664.02 331.97 0.05 Gross Profit 1,336.67 1,349.44 1,314.58 1,177.10 1,103.93 1,007.70 873.29 554.45 0.20 GP Margin 55.69% 56.54% 57.58% 54.46% 51.99% 53.45% 56.81% 62.55% 80.0% Total Expenditure 1,704.71 1,704.30 1,608.97 1,518.93 1,507.15 1,294.09 1,065.35 639.25 0.26 Power & Fuel Cost - 117.24 112.46 115.60 100.92 74.19 76.75 57.81 0.00 % Of Sales - 4.91% 4.93% 5.35% 4.75% 3.94% 4.99% 6.52% 0% Employee Cost - 251.70 258.16 180.18 168.72 149.13 142.28 106.28 0.15 % Of Sales - 10.55% 11.31% 8.34% 7.95% 7.91% 9.26% 11.99% 60.0% Manufacturing Exp. - 177.41 163.63 137.17 124.04 107.61 108.03 77.23 0.04 % Of Sales - 7.43% 7.17% 6.35% 5.84% 5.71% 7.03% 8.71% 16.00% General & Admin Exp. - 52.56 55.14 46.45 54.18 43.36 44.09 29.51 0.02 % Of Sales - 2.20% 2.42% 2.15% 2.55% 2.30% 2.87% 3.33% 8.00% Selling & Distn. Exp. - 53.92 38.52 45.10 31.78 33.79 26.32 27.91 0.00 % Of Sales - 2.26% 1.69% 2.09% 1.50% 1.79% 1.71% 3.15% 0% Miscellaneous Exp. - 14.03 12.41 10.30 8.23 8.54 3.86 8.53 0.00 % Of Sales - 0.59% 0.54% 0.48% 0.39% 0.45% 0.25% 0.96% 0% EBITDA 695.41 682.58 674.24 642.29 616.06 591.07 471.96 247.17 -0.01 EBITDA Margin 28.97% 28.60% 29.53% 29.72% 29.02% 31.35% 30.70% 27.88% -4.00% Other Income 38.06 34.57 12.04 28.96 14.70 0.81 11.99 0.99 0.00 Interest 3.31 2.41 1.55 0.55 27.96 87.55 33.52 0.61 0.00 Depreciation 63.28 60.61 53.45 42.09 37.88 33.39 29.37 19.26 0.00 PBT 666.88 654.13 631.29 628.61 564.92 470.94 421.07 228.30 -0.01 Tax 171.20 168.50 160.40 161.65 146.20 119.36 107.97 32.70 0.42 Tax Rate 25.67% 25.76% 25.41% 25.72% 25.88% 25.35% 25.64% 14.32% -4200.00% PAT 495.68 485.63 470.89 466.96 418.72 351.58 313.10 195.59 -0.43 PAT before Minority Interest 495.68 485.63 470.89 466.96 418.72 351.58 313.10 195.59 -0.43 Minority Interest 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 PAT Margin 20.65% 20.35% 20.62% 21.61% 19.72% 18.65% 20.37% 22.07% -172.00% PAT Growth 10.91% 3.13% 0.84% 11.52% 19.10% 12.29% 60.08% - EPS 40.40 39.58 38.38 38.06 34.13 28.65 25.52 15.94 -0.04

Results Balance Sheet

Standalone Figures in Rs. Crores

Right to Left

Description Mar 25 Mar 24 Mar 23 Mar 22 Mar 21 Mar 20 Mar 19 Mar 18
Shareholder's Funds 2,817.37 2,332.32 2,138.21 2,054.31 752.75 401.69 88.13 -1.40 Share Capital 24.51 24.50 24.50 24.50 1.96 1.96 1.96 0.01 Total Reserves 2,782.90 2,296.76 2,107.02 2,026.31 750.79 399.73 86.17 -1.41 Non-Current Liabilities 466.05 756.95 67.40 32.70 22.89 16.45 6.86 0.00 Secured Loans 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Unsecured Loans 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Long Term Provisions 360.67 693.40 7.87 0.00 0.00 0.00 0.00 0.00 Current Liabilities 470.16 438.77 1,014.89 746.80 1,444.93 1,307.46 1,380.41 1.48 Trade Payables 390.46 368.66 427.23 307.72 221.31 201.07 182.89 0.01 Other Current Liabilities 62.74 58.08 54.57 49.84 966.54 1,084.03 1,181.11 1.46 Short Term Borrowings 0.00 0.00 0.00 0.00 0.00 0.02 0.02 0.00 Short Term Provisions 16.96 12.03 533.09 389.24 257.08 22.34 16.40 0.01 Total Liabilities 3,753.58 3,528.04 3,220.50 2,833.81 2,220.57 1,725.60 1,475.40 0.08 Net Block 954.95 805.06 780.63 589.76 572.80 546.25 456.31 0.00 Gross Block 1,218.71 1,012.33 936.48 705.53 651.90 594.82 475.57 0.00 Accumulated Depreciation 263.76 207.26 155.85 115.77 79.10 48.58 19.26 0.00 Non Current Assets 1,418.43 1,612.05 851.81 706.42 598.03 565.49 544.70 0.00 Capital Work in Progress 101.91 105.99 61.62 96.95 14.10 10.73 80.39 0.00 Non Current Investment 0.08 0.08 0.08 0.08 0.08 0.08 0.08 0.00 Long Term Loans & Adv. 361.49 700.92 9.49 19.63 11.06 8.44 7.92 0.00 Other Non Current Assets 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Current Assets 2,335.16 1,916.00 2,368.68 2,127.39 1,622.53 1,160.11 930.70 0.08 Current Investments 477.62 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Inventories 673.95 666.59 604.17 516.24 513.42 412.77 400.84 0.04 Sundry Debtors 969.74 765.43 806.77 673.49 619.50 638.63 448.09 0.03 Cash & Bank 71.24 301.59 309.40 512.16 115.60 10.00 2.06 0.01 Other Current Assets 142.62 91.69 71.72 5.96 374.01 98.71 79.70 0.01 Short Term Loans & Adv. 100.37 90.69 576.63 419.54 303.70 65.00 18.04 0.01 Net Current Assets 1,865.00 1,477.23 1,353.80 1,380.59 177.60 -147.35 -449.72 -1.40 Total Assets 3,753.59 3,528.05 3,220.49 2,833.81 2,220.56 1,725.60 1,475.40 0.08

Cash Flow

Standalone Figures in Rs. Crores

Right to Left

Description Mar 25 Mar 24 Mar 23 Mar 22 Mar 21 Mar 20 Mar 19 Mar 18
Cash From Operating Activity 391.52 413.51 306.01 597.59 388.11 195.01 10.35 -0.48 PBT 654.13 631.29 628.61 564.92 470.94 421.07 228.30 -0.01 Adjustment 80.72 79.27 44.62 70.99 133.31 56.74 -101.15 0.00 Changes in Working Capital -180.38 -134.08 -213.66 99.84 -107.58 -190.26 -93.26 -0.47 Cash after chg. in Working capital 554.48 576.48 459.57 735.75 496.68 287.54 33.89 -0.48 Interest Paid 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Tax Paid -162.95 -162.96 -153.56 -138.17 -108.56 -92.54 -23.54 0.00 Other Direct Exp. Paid 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Extra & Other Items 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Cash From Investing Activity -615.64 -116.48 -146.75 -122.23 -68.73 -50.52 -8.91 0.00 Net Fixed Assets -202.30 -120.22 -195.62 -136.48 -60.45 -49.59 -555.96 Net Investments -477.62 0.00 0.00 0.00 0.00 0.00 -0.08 Others 64.28 3.74 48.87 14.25 -8.28 -0.93 547.13 Cash from Financing Activity -6.23 -279.44 -387.59 -78.80 -213.78 -136.55 0.54 0.49 Net Cash Inflow / Outflow -230.35 17.59 -228.33 396.56 105.60 7.94 1.97 0.01 Opening Cash & Equivalents 301.41 283.82 512.16 115.60 10.00 2.06 0.01 0.00 Closing Cash & Equivalent 71.06 301.41 283.82 512.16 115.60 10.00 2.06 0.01

Financial Ratios

Standalone

Right to Left

Description Mar 25 Mar 24 Mar 23 Mar 22 Mar 21 Mar 20 Mar 19 Mar 18
Book Value (Rs.) 229.11 189.45 173.97 167.38 69.83 37.26 449.62 -1398.00 ROA 13.34% 13.96% 15.43% 16.57% 17.82% 19.56% 26.51% -510.59% ROE 18.94% 21.15% 22.33% 29.87% 60.91% 127.84% 451.05% 0.00% ROCE 25.50% 28.31% 30.01% 42.24% 96.75% 185.60% 527.74% 0.00% Fixed Asset Turnover 2.15 2.35 2.65 3.13 3.03 2.88 3.73 248.00 Receivable days 132.12 125.30 124.34 111.01 121.50 128.84 92.26 45.63 Inventory Days 102.08 101.28 94.11 88.40 89.45 96.46 82.54 55.93 Payable days 133.54 149.95 136.29 94.72 87.85 65.75 52.18 24.84 Cash Conversion Cycle 100.66 76.63 82.16 104.69 123.10 159.54 122.62 76.71 Total Debt/Equity 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Interest Cover 271.97 409.34 1150.19 21.20 6.38 13.56 378.35 0.00

Top Investors:

polar capital funds plc - healthcare opportunities

quant mutual fund - quant small cap fund

massachusetts institute of technology

Annual Reports:

News Update:

Alivus Life Sciences - Quarterly Results
1st Aug 2025, 18:31 PM

Read More
USFDA issues EIR with NAI classification for Alivus Life Sciences’ API unit
28th Jul 2025, 11:53 AM

The USFDA had conducted an inspection from May 26, 2025 to May 30, 2025
Read More

Source: www.accordfintech.com | DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.

Feedback